1. Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B
- Author
-
Howard Levy, Frank Del Greco, Martin Lee, and Johnny Mahlangu
- Subjects
Adult ,Male ,medicine.medical_specialty ,Clinical Trials and Supportive Activities ,Clinical Sciences ,Thrombogenicity ,haemophilia B ,030204 cardiovascular system & hematology ,immunogenicity ,Haemophilia ,Hemophilia A ,Hemophilia B ,03 medical and health sciences ,0302 clinical medicine ,dalcinonacog alfa ,Pharmacokinetics ,Clinical Research ,Internal medicine ,medicine ,Humans ,Haemophilia B ,Dosing ,Clinical Haemophilia ,Genetics (clinical) ,Clotting factor ,factor IX ,business.industry ,Evaluation of treatments and therapeutic interventions ,clinical trial ,Original Articles ,General Medicine ,Hematology ,medicine.disease ,Clinical trial ,Tolerability ,Cardiovascular System & Hematology ,6.1 Pharmaceuticals ,Original Article ,subcutaneous ,Blood Coagulation Tests ,prophylaxis ,business ,030215 immunology ,Half-Life - Abstract
AimPhase 2b study to assess efficacy, safety, thrombogenicity, immunogenicity and tolerability with 28days of daily dosing of subcutaneous (SQ) dalcinonacog alfa as prophylaxis for haemophilia B (HB).MethodsAdult males with a confirmed diagnosis of congenital HB (factor IX [FIX] activity
- Published
- 2021